HIV progress is real, but the next decade may reverse hard-won gains
Global HIV mortality and incidence have fallen over the past two decades, yet the new Global Burden of Disease 2023 analysis makes the fragility of those gains hard to ignore. The study tracks HIV burden across 204 countries and territories from 1990 through 2023, then extends the picture into 2030 with forecasts tied to development assistance for health. It also places intimate partner violence squarely inside the epidemiology, quantifying how gendered exposure can translate into avoidable deaths among women.
The broad direction of travel has been favorable. Annual new infections fell from 2.85 million in 2003 to 2.06 million in 2023, while HIV-related deaths declined from a peak of 1.71 million in 2004 to 0.83 million in 2023. At the same time, the number of people living with HIV climbed from 26.3 million to 42.4 million, a reminder that better survival can coexist with a growing pool of people requiring long-term treatment. Expanded antiretroviral therapy has prolonged life, but it has also changed the shape of the epidemic rather than ending it.
The burden remains deeply unequal between regions and between sexes.
ART expansion lowered deaths, but prevalence kept rising
The central epidemiologic tension in the analysis is straightforward: fewer people are dying, yet more people are living with infection. That pattern fits the biology and public health logic of modern HIV care. When ART suppresses viral replication and prevents progression to AIDS, mortality drops and life expectancy improves, but prevalence can rise as survival lengthens. In other words, the treatment success of one generation becomes the chronic care burden of the next.
Sex patterns matter here. Females still carried a higher prevalence than males in 2023, with 23.4 million women and girls living with HIV compared with 19.1 million males. The incidence gap between females and males has narrowed substantially, suggesting progress in prevention and treatment access, but not enough to erase the structural drivers of risk. A shrinking incidence gap does not mean gender inequality has disappeared; it means the epidemic is still being shaped by social exposure, access to care, and vulnerability across the life course.
Regional differences were stark. Sub-Saharan Africa recorded the largest declines between 2003 and 2023, with incidence down 64.3% and mortality down 74.6%. Central Europe, eastern Europe, and central Asia moved in the opposite direction, posting a 232.1% increase in incidence rates and a 37.8% increase in mortality rates over the same period. Those trajectories suggest that HIV epidemiology is not governed by a single global mechanism. Treatment scale-up, prevention coverage, stigma, health-system capacity, and political commitment all move the curve in different directions.
Intimate partner violence adds a measurable share of female HIV mortality
The analysis of intimate partner violence is one of the most consequential elements of the paper. IPV was associated with an estimated 10.7% of HIV-related deaths among females aged 15 years and older globally in 2023, translating to 40,700 deaths. The population attributable fraction was highest in Oceania, central sub-Saharan Africa, and eastern sub-Saharan Africa.
This is not a marginal association. Violence can raise HIV risk through multiple pathways at once: coerced sex, reduced power to negotiate condom use, delayed testing, interrupted treatment, and barriers to disclosure or clinic attendance. Once HIV infection is established, the same violence can undermine adherence and continuity of care, increasing the risk of progression and death. The public health implication is direct. HIV programs that ignore violence prevention are leaving a major upstream driver untouched.
The estimates also force a broader reading of women’s HIV mortality. Viral suppression alone cannot fully offset repeated exposure to coercion, fear, and disrupted access to services. In settings where IPV remains common, the clinical pathway from violence to infection to worse survival is not abstract. It is a lived chain of risk that reaches the clinic door and often continues beyond it.
Forecasts point to a sharp penalty from funding cuts
The forecasting component is the most sobering part of the analysis. Using a non-parametric stochastic frontier approach, the investigators estimated how development assistance for health can influence ART coverage, then translated reduced coverage into future incidence and mortality. Under a scenario of funding reductions, global ART coverage could fall by 8.1% between 2025 and 2030.
The downstream effect is large. The forecasted consequences include approximately 1.6 million new HIV infections among females and 1.3 million among males, along with 790,600 HIV-related deaths among females and 670,600 among males by 2030. These effects are concentrated primarily in sub-Saharan Africa, where treatment programs remain highly dependent on external financing in many settings. When ART access contracts, viral suppression declines, transmission rises, and deaths follow with a lag that can look deceptively slow until the numbers accumulate.
The model links financing to physiology through a plausible public-health mechanism. Fewer funded treatment slots mean fewer patients retained on ART, more unsuppressed virus circulating in communities, and greater opportunity for onward transmission. At the bedside, this becomes a problem of refill interruptions, missed follow-up, and patients returning with advanced disease that should have been preventable.
The 2030 target depends on more than drug supply
The study’s implication for UNAIDS 2030 targets is blunt. Sustaining progress will require more than maintaining current treatment architecture. It will require financing stability, programs that address violence as part of HIV prevention and care, and health systems capable of absorbing shocks without losing patients from treatment.
Gender-responsive programming is not an optional supplement to HIV control; it is part of the causal pathway. Preventing IPV, identifying survivors early, and linking them to post-violence care can reduce HIV vulnerability and may lower mortality in populations where risk is concentrated. At the same time, protecting HIV financing is essential because treatment coverage is the engine that keeps incidence and mortality moving downward.
The analysis is also a reminder that global averages can conceal regional reversal. Sub-Saharan Africa improved substantially, yet remains the region most exposed to financing disruption. Central and eastern Europe and central Asia have moved in an unfavorable direction, showing that epidemics can worsen even in the era of effective therapy if prevention and access falter.
The final message is concrete: the HIV response has made major gains, but those gains sit on a narrow base. Interrupt ART coverage, and incidence and mortality climb. Leave intimate partner violence untreated as a health-system issue, and women continue to die from a burden that is partly preventable.
The forecasted toll through 2030 is not a distant abstraction; it is the projected price of policy failure.